The Effect of Lenalidomide Ointment on TNF-α Tissue Levels in Mice with Imiquimod-Induced Psoriasis
DOI:
https://doi.org/10.32007/jfacmedbagdad.6441959Keywords:
Lenalidomide, Immunomodulatory, Anti-inflammatory, Imiquimod-induced psoriasis in mice, TNF-αAbstract
Background: Lenalidomide is an immunomodulatory drug having notable anti-inflammatory, and anti-antineoplastic properties. Lenalidomide suppresses the production of pro-inflammatory cytokines that have been linked to a variety of hematologic malignancies. Lenalidomide enhances the immune system of the host by regulating T cell proliferation, which results in changes in inflammation that are related to the etiology of psoriasis.
Objectives: The objectives of this study were to determine the efficacy of lenalidomide as an ointment in treating mouse models of psoriasis as well as how it may affect TNF-α levels in skin tissue in different experimental groups.
Methods: The study was carried out between November 2021 and June 2022. 70 healthy male albino mice were randomly divided into 7 groups of 10 animals each. In groups (1, 2, 3, 4, 5 and 6), imiquimod produced psoriasis. Only imiquimod cream was administered to Group 1, after psoriasis induced, Clobetasol ointment was applied to Group 2, placebo ointment was applied to Group 3, and lenalidomide ointment (1%, 2%, and 3%) were applied to Groups (4, 5, and 6), respectively. Healthy mice were utilized as a comparative control in Group 7. SPSS was utilized for the statistical analysis of the data (version 26).
Results: Following lenalidomide treatment, the psoriatic region improved. Lenalidomide's effectiveness to treat imiquimod-induced mouse psoriasis was explained by the difference in tissue levels of TNF-α between the examined groups.
Conclusions: Findings suggest that different concentrations of lenalidomide ointment can improve mouse models of imiquimod-induced psoriasis. Histopathology and immunohistochemistry assays show that lenalidomide ointment was more effective and had no side effects that were associated with the use of the standard drugs.
Downloads
References
Petit RG, Cano A, Ortiz A, Espina M, Prat J, Muñoz M, et al. Psoriasis: From pathogenesis to pharmacological and nano-technological-based therapeutics. International Journal of Molecular Sciences. 2021;22(9):4983.
Ciuluvica C, Fulcheri M, Amerio P. Expressive suppression and negative affect, pathways of emotional dysregulation in psoriasis patients. Front Psychol. 2019;10:1907.
H Adbullah T, I Latif I, Kh Ibrahim K. Role of Tumor Necrosis Factor Alpha and Transforming Growth Factor Beta as Predictive Marker for Psoriasis Patients. Diyala Journal of Medicine [Internet]. 2020 Oct 5;19(1):1–7. Available from: http://djm.uodiyala.edu.iq/index.php/djm/article/view/583
Gautam S, Kumar U, Dada R. Yoga and its impact on chronic inflammatory autoimmune arthritis. Frontiers in Bioscience-Elite. 2020;13(1):77–116.
Abbas Kareem, Y. A.-T. A. N. (2021). Evaluation of IL-17, IL-18 and IL-22 as Vital indicators of Iraqi Patients with Psoriasis. Iraqi Journal of Biotechnology, 20, 103–108.
Hu P, Wang M, Gao H, Zheng A, Li J, Mu D, et al. The Role of Helper T Cells in Psoriasis. Frontiers in Immunology. 2021;12.
Saheb EJ, Al-Issa YAH, Mussa IS, Zghair KH. Incidence of toxoplasmosis in psoriasis patients and possible correlation with tumor necrosis factor-α. Baghdad Science Journal. 2020 Mar 1;17(1):214–9.
Bahir A.R. Mshimesh. Treatment of Mild to Moderate Plaque Psoriasis with Pimecrolimus, Clobetasol, or Calcipotriol Cream: A comparative study. J Fac Med Baghdad. 2016 Apr 3;58(1):42–43.
Paumgartten FJR. The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues. Ciência & Saúde Coletiva. 2019;24:3783–92.
Qiu Q, Lin Y, Ma Y, Li X, Liang J, Chen Z, et al. Exploring the emerging role of the gut microbiota and tumor microenvironment in cancer immunotherapy. Frontiers in Immunology. 2021;11:612202.
McComb S, Thiriot A, Akache B, Krishnan L, Stark F. Introduction to the immune system. In: Immunoproteomics. Springer; 2019. p. 1–24.
Abbott M, Ustoyev Y. Cancer and the immune system: the history and background of immunotherapy. In: Seminars in oncology nursing. Elsevier; 2019. p. 150923.
Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review of Hematology. 2018;11(9):715–26.
Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;6(1):1–20.
Sharma RK, Sharma MR, Mahendra A, Kumar S. Role of Inflammatory Cytokines in Pathophysiology of Psoriasis. Current Pharmacology Reports. 2022;1–7.
Kar M, Chourasiya Y, Maheshwari R, Tekade RK. Current developments in excipient science: implication of quantitative selection of each excipient in product development. In: Basic Fundamentals of Drug Delivery. Elsevier; 2019. p. 29–83.
Li Y, Yesharim O, Hurvitz I, Karnieli A, Fu S, Porat G, et al. Adiabatic geometric phase in fully nonlinear three-wave mixing. Physical Review A. 2020;101(3):033807.
Mahmood AM, Kareem A, Abd H, Qasim BJ. NOVEL MITOXANTRONE HCL OINTMENT FORMULA VERSUS CLOBETASOL FOR TREATMENT OF PSORIASIS IN MICE [Internet]. Available from: https://connectjournals.com/
Amalia SN, Uchiyama A, Baral H, Inoue Y, Yamazaki S, Fujiwara C, et al. Suppression of neuropeptide by botulinum toxin improves imiquimod-induced psoriasis-like dermatitis via the regulation of neuroimmune system. J Dermatol Sci. 2021;101(1):58–68.
Mohammed SS, Kadhim HM, Al-Sudani IM, Musatafa WW. Study the Topical Effect of Six Days Use of Different Lycopene Doses on Imiquimod-Induce Psoriasis-Like Skin Inflammation in Mice.
Farah K NN. Effects of Vitamin D3 on Methotrexate- Induced Jejunum Damage in Rats. Iraqi Journal of Pharmaceutical Sciences. 2020 Jun 25;29(1).
Sy J, Ang LC. Microtomy: cutting formalin-fixed, paraffin-embedded sections. Biobanking. 2019;269–78.
Farah K MQ. Gastro Protective Effect of Ethanolic Extract of Anchus astrigosa on Indomethacin-Induced Gastric Ulcer in Rats. Drugs and Cell Therapies in Hematology. 2021;10(3):1–18.
Hermann J, Noels H, Theelen W, Lellig M, Orth-Alampour S, Boor P, et al. Sample preparation of formalin-fixed paraffin-embedded tissue sections for MALDI-mass spectrometry imaging. Anal Bioanal Chem. 2020;412(6):1263–75.
Wang WQ, WFH, QW, LHY, LB, CC, ZJ, GQ, SW and WC. Joint antiangiogenic effect of ATN-161 and anti-VEGF antibody in a rat model of early wet age-related macular degeneration. Mol Pharm. 2016;
Tan L, Zhao S, Zhu W, Wu L, Li J, Shen M, et al. The Akkermansia muciniphila is a gut microbiota signature in psoriasis. Exp Dermatol. 2018;27(2):144–9.
Jabeen M, Boisgard AS, Danoy A, el Kholti N, Salvi JP, Boulieu R, et al. Advanced characterization of imiquimod-induced psoriasis-like mouse model. Pharmaceutics. 2020;12(9):789.
Schön MP, Manzke V, Erpenbeck L. Animal models of psoriasis—highlights and drawbacks. Journal of Allergy and Clinical Immunology. 2021;147(2):439–55.
Li Y, Zhang G, Chen M, Tong M, Zhao M, Tang F, et al. Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice. Biomedicine & Pharmacotherapy. 2019;109:1876–83.
Heath MS, Kolli SS, Dowling JR, Cline A, Feldman SR. Pharmacotherapeutic strategies for standard treatment-resistant psoriasis. Expert Opinion on Pharmacotherapy. 2019;20(4):443–54.
Maroto-Morales D, Montero-Vilchez T, Arias-Santiago S. Study of skin barrier function in psoriasis: The impact of emollients. Life. 2021;11(7):651.
Kim HR, Mun Y, Lee KS, Park YJ, Park JS, Park JH, et al. T cell microvilli constitute immunological synaptosomes that carry messages to antigen-presenting cells. Nat Commun. 2018;9(1):1–19.
Thokchom SK, Gulati K, Thakur T, Rai N, Ray A. Dendritic Cells and Immunomodulation: Role in Health and Disease. Current Immunology Reviews. 2017;13(2):132–43.
Liu F, Huang J, Liu X, Cheng Q, Luo C, Liu Z. CTLA-4 correlates with immune and clinical characteristics of glioma. Cancer Cell Int. 2020;20(1):1–10.
ElTanbouly MA, Noelle RJ. Rethinking peripheral T cell tolerance: checkpoints across a T cell’s journey. Nature Reviews Immunology. 2021;21(4):257–67.
Gudi RR, Karumuthil-Melethil S, Perez N, Li G, Vasu C. Engineered dendritic cell-directed concurrent activation of multiple T cell inhibitory pathways induces robust immune tolerance. Sci Rep. 2019;9(1):1–16.
Tageja N. Lenalidomide-current understanding of mechanistic properties. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2011;11(3):315–26.
D’Souza C, Prince HM, Neeson PJ. Understanding the role of T-cells in the antimyeloma effect of immunomodulatory drugs. Frontiers in Immunology. 2021;12:632399.
Costache DO, Feroiu O, Ghilencea A, Georgescu M, Căruntu A, Căruntu C, et al. Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis. International Journal of Molecular Sciences. 2022;23(9):5198.
Pervaiz N, Kaur H, Parsad D, Kumar R. Immune‐
modulatory effects of lenalidomide inhibited the
progression of lesions in a vitiligo mouse model. Pigment Cell & Melanoma Research. 2021;34(5):918–27.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 sajjad Mustafa Thamer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
For all articles published in Journal of the Faculty of Medicine Baghdad, copyright is retained by the authors. Articles are licensed under an open access Creative Commons CC BY NC 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work, while ensuring that the authors receive proper rights.
How to Cite
Creative Commons Attribution 4.0 International license..
